What is the latest selling price of Sorafenib/Nexavar in 2025?

As of October 2025, Sorafenib/Nexavar (Sorafenib) has been officially launched in China for many years and has been included in the National Reimbursement Directory for the treatment of advanced hepatocellular carcinoma, renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer. As an original anti-cancer targeted drug, sorafenib has long been expensive. However, with the continued advancement of localization and medical insurance negotiations, its market price has dropped significantly, bringing economic accessibility to more patients.

The original research sorafenib currently on the market in China is produced by Bayer Pharmaceuticals. The common specification is 0.2g × 60 tablets. The price per box is about RMB 6,000. After being included in medical insurance, the patient's out-of-pocket payment ratio has been significantly reduced. According to different medical insurance reimbursement policies in some provinces and cities, the actual payment may be only about half of the original price. Since the drug is a long-term oral drug, the implementation of the medical insurance policy has significantly reduced the financial burden on patients and promoted its popularity in the treatment of liver cancer and kidney cancer.

It is worth noting that there are many generic versions of sorafenib on the overseas market, including preparations produced by some pharmaceutical companies in Laos, Bangladesh, Vietnam and India. These generic drugs are consistent with the original drugs in terms of active ingredients and dosage specifications, and are generally in the form of 50mg or 100mg tablets, but are more affordable. According to information from unofficial channels, the price of some Laotian generic versions may only be around RMB 800 per box. If patients need to use it, they should carefully check the source and legality of the drug.

The global market competition for sorafenib will become increasingly fierce in 2025. With the emergence of multiple new TKI drugs (such as lenvatinib and cabozantinib), the pricing strategy of sorafenib will also become stable and transparent. Bayer still maintains its brand advantage in the Asia-Pacific region, and at the same time cooperates with pharmaceutical companies in many places to promote price localization to comply with the medical insurance policies of different countries.

Reference materials:https://www.nexavar.com/